Lilly gains Prozac indications
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Lilly's Prozac (fluoxetine) gains additional indications July 29 for panic disorder, with and without agoraphobia, and longer-term treatment of bulimia. Labeling adds 52-week follow-up data to existing 16-week studies in bulimia; the panic studies were 12 weeks long. Lilly had expected Prozac exclusivity to run until June 2004, but a court decision in August 2001 invalidated its longest-running patents, allowing generics to come to marke